Moderna Reports Encouraging Early Results for Cancer Therapy

Moderna, Inc. has released early data from its Phase 1/2 study of the investigational therapy mRNA-4359 at the 2025 European Society for Medical Oncology (ESMO) Congress. The study evaluates the therapy in combination with pembrolizumab for patients with checkpoint inhibitor-resistant melanoma. mRNA-4359, targeting immune-evasion pathways, showed a 24% objective response rate and a 60% disease control rate among 29 participants. Notably, the response rate was 67% in patients with PD-L1+ tumors. The therapy demonstrated a manageable safety profile and offers potential as an effective treatment option for patients with advanced melanoma.

Dr. Kyle Holen of Moderna expressed optimism, highlighting the unique approach of mRNA-4359 in generating targeted T cells. Prof. David J. Pinato emphasized the promise of mRNA-4359 in overcoming immunotherapy resistance. As research continues, Moderna is optimistic about the role its mRNA-based therapies might play in cancer treatment.